Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial

Overview of attention for article published in Critical Care, June 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 15 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 26,423 followers.

RT @_aacw: Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 rando…

02 Jul 2022

Reply Repost Favourite

Plasma IL-18 is associated with increased mortality in ARDS, and may predict those who respond to simvastatin. Prospective evaluation and mechanistic studies needed ... +/- another simvastatin study😬 Paper below in @Crit_Care with @dfmcauley @msh_manu @ce

02 Jul 2022

Reply Repost Favourite

@doc_matt_jacko @DavidSapsford @ICS_updates I think this data (https://t.co/5dJSKbivFZ), and previous, from our group @dfmcauley might suggest the population to target with simvastatin are those with higher baseline inflammation, e.g. high IL-18 or hyperin

30 Jun 2022

Reply Repost Favourite

Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial : https://t.co/q5hNEu0i0D @_aboyle #SOA22

30 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.